ClinicalTrials.gg
CompletedNCT03538925Updated Jan 8, 2024

Building Sentences With Preschoolers Who Use AAC

A Phase 2 interventional study of AAC Generative Language Intervention and Standard of Care / Business as Usual in Down Syndrome, Speech and Language Disorder and Speech Disorders in Children, sponsored by University of Central Florida. Completed at 2 sites in United States. Open to participants aged 3 Years to 4 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by University of Central Florida · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
3 Years to 4 Years
Sex
All
01

Study summary

The focus of this investigation is to compare the effectiveness of the AAC Generative Language Intervention approach to an AAC Standard of Care condition on preschool sentence productions. All children will use existing AAC iPad applications.

Read the detailed description

The central hypothesis is that preschoolers receiving AAC Generative Language Intervention will create longer, more grammatically complete sentences compared with the Standard of Care condition. Specific Aim 1 compares these interventions for preschoolers with severe speech impairments and typical receptive language, and Specific Aim 2 does the same for children with Down syndrome. Specific Aim 3 tests for possible moderation of the intervention effect by age, dynamic assessment scores, sentence type, receptive language abilities, prior AAC use, sex, mental age, and disability. Aims 1 and 2 will be accomplished using randomized controlled trials.

02

Conditions studied

  • Down Syndrome
  • Speech and Language Disorder
  • Speech Disorders in Children
  • Speech Intelligibility
  • Speech Sound Disorder
03

In context

Down Syndrome

438 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

This study's enrollment of 70 is above the median of 37 across 286 interventional studies indexed under Down Syndrome.

Browse Down Syndrome studies →

Lead sponsor

University of Central Florida is the lead sponsor of 104 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Identification of Significant Speech Impairment
  • Must Speak English as a Primary Language
  • Must Be Able to Express At Least 25 Words (using any communication mode)
  • Must Be Able to Accurately Select Picture Symbols on iPad Communication App with at Least 50% Accuracy
  • Vision and Hearing within Functional Limits or Corrected to be within Functional Limits for Study Activities

Exclusion criteria

Exclusion Criteria:

  • Clinical Diagnosis of Autism or Social Communication Disorder
  • Primary Language Spoken is a Language Other than English
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment Group

    AAC Generative Language Intervention

    Behavioral: AAC Generative Language Intervention · Behavioral: Standard of Care / Business as Usual

  • Active comparator
    Business as Usual

    Standard of Care / Business as Usual

    Behavioral: Standard of Care / Business as Usual

Interventions

  • BehavioralAAC Generative Language Intervention

    Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention

  • BehavioralStandard of Care / Business as Usual

    Parent/Caregiver AAC App Operational Training

06

What researchers measure

Primary outcomes

  1. Aided AAC Utterance Length

    Aided AAC sentence length measured in morphemes

    Time frame: 6 Months

07

Study locations

2 sites
  • FAAST Center at the University of Central Florida
    Orlando, Florida 32826, United States
  • University of New Mexico Department of Speech and Hearing Sciences
    Albuquerque, New Mexico 87131, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03538925
Responsible party
Sponsor
First posted
May 29, 2018
Start date
May 11, 2018
Primary completion
Jun 30, 2023
Completion
Dec 31, 2023
Last update
Jan 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion